What does “Xtandi” have to do with the United States?
Xtandi is the brand name for enzalutamide, an oral treatment used for certain stages of prostate cancer in the United States. The U.S. regulatory status and availability of Xtandi depend on the specific prostate cancer setting being treated (for example, metastatic hormone-sensitive vs. metastatic castration-resistant disease).
Which U.S. drug approvals apply to Xtandi (enzalutamide)?
Because “Loe xtandi united states” is unclear as written, the most useful way to answer is by U.S. indication. In general, enzalutamide has had multiple U.S. approvals tied to different prostate cancer disease states, and those approvals control how Xtandi can be prescribed and reimbursed in the U.S.
Patent or exclusivity questions: who controls Xtandi in the U.S.?
If your goal is “who owns Xtandi in the U.S.” or “when does it lose exclusivity/patent protection,” that depends on:
- the specific patent(s) covering enzalutamide in each indication,
- patent expiration and any regulatory exclusivity extensions,
- and whether generic or biosimilar-like competition is possible (for small-molecule enzalutamide, the key issue is generic entry rather than biosimilars).
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Xtandi and can help pinpoint likely timelines in the U.S.: https://www.drugpatentwatch.com/
Are there generic versions of Xtandi in the United States?
Whether a generic enzalutamide product is available in the U.S. depends on patent and exclusivity status for enzalutamide. If you’re trying to find out if generic Xtandi exists (or when it might arrive), the fastest path is to check the latest U.S. patent/exclusivity status on DrugPatentWatch.com: https://www.drugpatentwatch.com/
What exactly should I look up—drug status, patents, or cost in the U.S.?
To give a precise answer, tell me what you meant by “Loe” (for example: “lose,” “look up,” “list,” or “LOE” for “loss of exclusivity”) and what you need in the U.S.:
- current FDA indication/status,
- patent expiration / loss of exclusivity date,
- generic competition status,
- or pricing/reimbursement.
Reply with one of those options and I’ll narrow it to the correct U.S. details.
Sources
- [1] https://www.drugpatentwatch.com/ (DrugPatentWatch.com)